Patent ID: 7671049

Claim:
A method for treating a GSK 3 -mediated disorder in a human or animal subject, comprising administering to the human or animal subject an amount of a compound of structure III effective to inhibit GSK 3 activity in the subject: wherein W is absent or is selected from the group consisting of —O—, —S—, —S(O)—, —SO 2 —, —NH—, —NH—CO—, —NR′CO—, —NHSO 2 —, —NR′SO 2 —, —CO—, —CO 2 —, —CH 2 —, —CF 2 —, CHF, —CONH—, —CONR′—, and —NR′—, where R′ is alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo; R 2 and R 3 are independently selected from the group consisting of hydrogen, hydroxyl, and optionally substituted loweralkyl, cycloloweralkyl, cyclicaminoalkyl, alkylaminoalkyl, loweralkoxy, amino, alkylamino, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, and aryl; R 5 and R 8 are independently selected from the group consisting of hydrogen, halo, and optionally substituted loweralkyl, cycloalkyl, alkoxy, amino, aminoalkoxy, carbonyloxy, aminocarbonyloxy, alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, cycloimido, amidino, cycloamidino, guanidinyl, aryl, biaryl, and arylsulfonamido; R 6 is selected from the group consisting of hydrogen and optionally substituted aryl; R 7 is selected from the group consisting of hydrogen, hydroxy, halo, carboxyl, nitro, amino, amido, amidino, imido, cyano, sulfonyl, methanesulfonyl, and substituted or unsubstituted alkyl, alkoxy, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, alkylaminocarbonyloxy, arylamino-carbonyloxy, formyl, loweralkylcarbonyl, loweralkoxycarbonyl, aminocarbonyl, aminoaryl, alkylsulfonyl, sulfonamido, aminoalkoxy, alkylamino, alkylcarbonylamino, alkylaminocarbonylamino, arylaminocarbonylamino, aralkylcarbonylamino, arylcarbonylamino, cycloamido, cyclothioamido, cycloamidino, cycloalkyl, cycloimido, guanidinyl, aryl, arylsulfonyl and arylsulfonamido; R 9 and R 10 are independently selected from the group consisting of hydrogen, hydroxy, nitro, amino, cyano, halo, thioamido, amidino, oxamidino, alkoxyamidino, imidino, guanidinyl, sulfonamido, carboxyl, formyl, loweralkyl, aminoloweralkyl, loweralkylaminoloweralkyl, haloloweralkyl, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, loweralkylaminoloweralkoxy, loweralkylcarbonyl, loweraralkylcarbonyl, lowerheteroaralkylcarbonyl, alkylthio, aryl and aralkyl; the tautomers thereof; or a pharmaceutically acceptable salt thereof; wherein said GSK3-mediated disorder is selected from the group consisting of diabetes, obesity and syndrome X.